PlateletBio will use the funds to continue preclinical development of its lead PLC therapy for immune thrombocytopenia, further develop its engineered PLC platform, and advance its proprietary manufacturing capabilities. PLCs are capable of performing vital biological functions and can be genetically engineered into multiple allogeneic cell therapies, the company said.

The round included new investors, including SymBiosis, K2 HealthVentures, and Oxford Finance, as well as existing investors Ziff Capital Partners and Qiming Venture Partners, the company said.